Business
Neuronetics Announces Key Role for NeuroStar Advanced Therapy at 4th International Brain Stimulation Conference
Symposium to Highlight World’s Largest Depression Outcomes Registry MALVERN, Pa., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a
About this update from Neuronetics, Inc.
[{"type":"text","content":"Symposium to Highlight World’s Largest Depression Outcomes Registry\nMALVERN, Pa., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their leadership role at the 4th International Brain Stimulation Conference December 6-9 in Charleston, South Carolina as the Platinum Sponsor of the conference. “We are honored to attend and participate in the 4th International Brain Stimulation Conference, an important meeting that takes a multidisciplinary approach to the science that is driving advances in this field,” said Keith J. Sullivan, President and CEO of Neuronetics. “NeuroStar® Advanced Therapy has pioneered the industry with breakthrough technology, using transcranial magnetic stimulation (TMS) to treat major depressive disorder. Through our sponsorship, we demonstrate our continued commitment to furthering the scientific discussion and research around treatment and outcomes.” NeuroStar data will be featured in a general session symposium entitled “What Can a Large TMS Registry Database Inform Us About Treatment Outcomes?”, during which industry leaders will discuss the following: Dr. Scott Aaronson, Director, Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt Health System, provides an overview of the large transcranial magnetic stimulation patient outcomes database.Dr. Harold Sackeim, Professor of Clinical Psychology in Psychiatry and Radiology at Columbia University, compares clinical outcomes with left unilateral and sequential bilateral transcranial magnetic stimulation treatment of major depressive disorder in a large patient registry.Dr. Todd Hutton, Medical Director at Southern California TMS Center, discusses the repetitive transcranial magnetic stimulation therapy markedly reduces anxiety in adults with major depressive disorder.Dr. Linda Carpenter, Professor of Psychiatry at the Brown University in the Brown Department of Psychiatry and Human Behavior, reviews the NeuroStar transcranial magnetic stimulation registry database and reveals the effects of patient demographics and stimulation parameters on treatment outcomes. “I am delighted to be sharing the podium with my esteemed colleagu...